Host-Based Diagnostics for Acute Infections
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
W6QK ACC-APG
Contract Value
Not provided
Codes & Classification
Solicitation Number
W911SR26RHDAI
NAICS
-
Classification Code
-
Additional Details
The Department of Defense, through the Department of the Army and its contracting office W6QK ACC-APG, has issued a Sources Sought notice (Procurement Identifier: W911SR26RHDAI) seeking industry input for the development of host-based diagnostics for acute infections. This Request for Information (RFI) is part of the Advanced Differential Diagnostics (ADD) program, a Program of Record managed by the Capability Program Executive for Chemical, Biological, Radiological and Nuclear Defense (CPE CBRND). The initiative is focused on advancing diagnostic technologies that leverage the warfighter’s physiological response to pathogens, with the ultimate goal of enhancing military medical readiness and resilience against CBRN (chemical, biological, radiological, and nuclear) threats.
Purpose and Scope:
The primary objective of this RFI is to identify mature diagnostic candidates (preferably at Technology Readiness Level (TRL) 4 or higher) that utilize host biomarkers—such as gene expression patterns in peripheral blood or other minimally invasive sample types—to diagnose disease etiology, predict clinical outcomes, and guide therapeutic interventions. The envisioned diagnostics should enable rapid, accurate decision-making in both remote and central clinical laboratory settings, supporting operational needs across the conflict continuum. The intended outcomes are improved diagnosis, prognostication, and treatment selection for acute infections, particularly those resulting from biowarfare agents, thereby reducing severity, duration, and hospitalization, and facilitating a faster return to duty.
Key Requirements and Deliverables:
CPE CBRND is seeking information from organizations developing innovative, host-directed diagnostic solutions that:
- Predict complications such as sepsis, SIRS, respiratory destabilization, or other acute outcomes based on measurable host biomarkers.
- Assist in therapeutic selection and monitoring, enabling precision medicine approaches and identifying effective or ineffective responses to treatment, especially in cases of hyperinflammatory states or immune paralysis.
- Meet the following ideal product profile:
- Intended for use alongside clinical assessments to determine likelihood of severe outcomes and inform therapeutic choices.
- Compact, robust devices suitable for low-resource environments (handheld or backpack-sized, battery or externally powered, operable in tropical conditions), with assay times ideally under 10 minutes (maximum 70 minutes).
- Clinical sensitivity and specificity exceeding 90%.
- Compatible with peripheral blood (EDTA or PAXgene-stabilized), fingerstick blood, respiratory, or other minimally invasive sample types.
Respondents are requested to submit a concise white paper (maximum three pages) and a one-page Quad Chart addressing:
- Technical Approach and Product Maturity: Description of the diagnostic’s targeted host response, TRL assessment, and summary of diagnostic efficacy data.
- Regulatory and Clinical Status: History of FDA engagement, status of regulatory applications, and summary of clinical trial data.
- Manufacturing and Supply Chain: Current manufacturing capabilities, scalability strategy, and sourcing of key starting materials.
- Company Profile and Vision: Corporate experience in advanced product development, prior success in transitioning products to advanced development or licensure, and teaming strategies.
Contracting Entity and Location:
The contracting entity is W6QK ACC-APG, a federal office under the Department of Defense, Department of the Army. The place of performance is Frederick, Maryland, United States.
Procurement Type and Special Considerations:
This notice is strictly a Sources Sought/RFI for market research and planning purposes. It is not a solicitation, and no contract will be awarded based on responses. The government is not committed to any supply or service as a result of this notice, and respondents are responsible for their own expenses. Proprietary or classified information should not be included in submissions. The government’s primary interest is in scientifically mature and programmatically viable candidates, with emphasis on technical approach, product maturity, and regulatory/clinical status.
Contact Information:
Responses and inquiries should be directed to:
- [email protected]
- Keith Pereira, Contract Specialist: [email protected]
Additional Details:
- Notice posted on April 24, 2026; responses are due by May 22, 2026.
- Notice status is active and can be accessed via SAM.gov (Opportunity ID: 5abb5c93153b4920b09fe802f9b45f6a).
This opportunity is well-suited for organizations with advanced diagnostic technologies, robust manufacturing capabilities, and experience in regulatory and clinical development. It offers a unique chance to influence the future of military medicine and contribute to the protection and resilience of U.S. armed forces against CBRN threats.